BCIQ Profiles

Company Profile ReportTarget Profile Report
0525 ECP Epygenix
BioCentury & Getty Images

Emerging Company Profile

EpyGenix: Fishing for best in class in epilepsy

EpyGenix’s zebrafish Dravet model yields three repurposed molecules with best-in-class potential

EpyGenix is leveraging a UCSF-originated animal model of Dravet syndrome to identify three repurposed molecules that have best-in-class potential in rare epilepsies.

May 26, 2021 | 12:44 AM GMT

EpyGenix has leveraged its animal model of Dravet syndrome to identify three repurposed molecules that have shown high levels of preclinical efficacy. The biotech is hoping the well-established safety profiles of each molecule gives them best-in-class potential.

EpyGenix

Read the full 903 word article

How to gain access

Continue reading with a
two-week free trial.